6 days Ago By Defense World Staff
Alliancebernstein L.P. boosted its position in shares of Biohaven Ltd.
(NYSE:BHVN – Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 96,236 shares of the company’s stock after buying an additional 5,951 shares during the period.
Alliancebernstein L.P. owned 0.
10% of Biohaven worth $3,594,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors also recently bought and sold shares of BHVN. Spire Wealth Management purchased a new stake in Biohaven during the fourth quarter worth about $56,000.
Amalgamated Bank increased its stake in Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after purchasing an additional 527 shares in the last quarter.
US Bancorp DE raised its holdings in Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company’s stock worth $111,000 after purchasing an additional 798 shares during the last quarter.
KBC Group NV raised its holdings in Biohaven by 50.1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company’s stock worth $126,000 after purchasing an additional 1,127 shares during the last quarter.
Finally, Diversified Trust Co boosted its position in Biohaven by 16.6% during the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock worth $209,000 after purchasing an additional 795 shares in the last quarter.
88.78% of the stock is owned by hedge funds and other institutional investors. Biohaven Trading Up 4.
7 %Shares of NYSE BHVN opened at $18.45 on Tuesday. Biohaven Ltd.
has a 12-month low of $15.79 and a 12-month high of $55.70.
The company has a market cap of $1.88 billion, a P/E ratio of -1.97 and a beta of 1.
33. The stock has a fifty day moving average price of $30.03 and a 200 day moving average price of $39.
27. Biohaven (NYSE:BHVN – Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.
85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29).
On average, sell-side analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.
Analyst Upgrades and DowngradesSeveral analysts have issued reports on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th.
JPMorgan Chase & Co. reduced their target price on Biohaven from $72.00 to $68.
00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 price target on Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th.
HC Wainwright restated a “buy” rating and issued a $54.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th.
Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Biohaven has a consensus rating of “Buy” and an average target price of $62.
77.Read Our Latest Analysis on BiohavenInsiders Place Their BetsIn related news, Director John W. Childs acquired 32,700 shares of Biohaven stock in a transaction that occurred on Tuesday, March 4th.
The stock was acquired at an average price of $30.47 per share, for a total transaction of $996,369.00.
Following the transaction, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. This trade represents a 1.
43 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 16.
00% of the stock is currently owned by corporate insiders. Biohaven Profile (Free Report)Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.See AlsoFive stocks we like better than BiohavenFind and Profitably Trade Stocks at 52-Week LowsWhy NVIDIA Stock Could Soar Despite Wall Street DowngradesStock Analyst Ratings and Canadian Analyst RatingsTop 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldWhat is a Secondary Public Offering? What Investors Need to Know3 Hot New IPOs Defying the 2025 Market SlumpWant to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd.
(NYSE:BHVN – Free Report)..
